PT3079688T - Derivado de cromona como um antagonista do receptor d3 de dopamina para seu uso para o tratamento de transtorno do espectro autista - Google Patents

Derivado de cromona como um antagonista do receptor d3 de dopamina para seu uso para o tratamento de transtorno do espectro autista Download PDF

Info

Publication number
PT3079688T
PT3079688T PT148124654T PT14812465T PT3079688T PT 3079688 T PT3079688 T PT 3079688T PT 148124654 T PT148124654 T PT 148124654T PT 14812465 T PT14812465 T PT 14812465T PT 3079688 T PT3079688 T PT 3079688T
Authority
PT
Portugal
Prior art keywords
dopamine
receptor
asd
treatment
pharmaceutically acceptable
Prior art date
Application number
PT148124654T
Other languages
English (en)
Portuguese (pt)
Inventor
Auclair Agnès
Moser Paul
Sokoloff Pierre
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PT3079688T publication Critical patent/PT3079688T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT148124654T 2013-12-13 2014-12-12 Derivado de cromona como um antagonista do receptor d3 de dopamina para seu uso para o tratamento de transtorno do espectro autista PT3079688T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13

Publications (1)

Publication Number Publication Date
PT3079688T true PT3079688T (pt) 2018-02-28

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148124654T PT3079688T (pt) 2013-12-13 2014-12-12 Derivado de cromona como um antagonista do receptor d3 de dopamina para seu uso para o tratamento de transtorno do espectro autista

Country Status (29)

Country Link
US (1) US10028948B2 (https=)
EP (1) EP3079688B1 (https=)
JP (1) JP6419826B2 (https=)
KR (1) KR102280530B1 (https=)
CN (1) CN105792824B (https=)
AU (1) AU2014363428B2 (https=)
BR (1) BR112016012552A8 (https=)
CA (1) CA2932791C (https=)
CY (1) CY1119907T1 (https=)
DK (1) DK3079688T3 (https=)
ES (1) ES2657706T3 (https=)
HR (1) HRP20180323T8 (https=)
HU (1) HUE036035T2 (https=)
IL (1) IL245996B (https=)
LT (1) LT3079688T (https=)
MA (1) MA39076A1 (https=)
MX (1) MX372922B (https=)
MY (1) MY172937A (https=)
NO (1) NO3079688T3 (https=)
NZ (1) NZ720868A (https=)
PL (1) PL3079688T3 (https=)
PT (1) PT3079688T (https=)
RS (1) RS56931B1 (https=)
RU (2) RU2019104946A (https=)
SA (1) SA516371298B1 (https=)
SI (1) SI3079688T1 (https=)
TN (1) TN2016000213A1 (https=)
UA (1) UA117271C2 (https=)
WO (1) WO2015086836A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53866B1 (sr) 2008-07-16 2015-08-31 Richter Gedeon Nyrt. Farmaceutske formulacije koje sadrže ligande dopaminskih receptora
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
TWI884984B (zh) * 2019-09-11 2025-06-01 英商牛津生物力學公眾有限公司 診斷染色體標記
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
WO2000021951A1 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
CA2580619C (en) * 2004-09-20 2013-11-12 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
US20110294879A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
FR2976179A1 (fr) * 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
WO2015086836A1 (en) 2015-06-18
CY1119907T1 (el) 2018-06-27
MY172937A (en) 2019-12-16
ES2657706T3 (es) 2018-03-06
RU2686110C1 (ru) 2019-04-24
IL245996A0 (en) 2016-07-31
IL245996B (en) 2018-11-29
US10028948B2 (en) 2018-07-24
HRP20180323T1 (hr) 2018-04-06
RU2019104946A (ru) 2019-04-01
EP3079688B1 (en) 2017-11-22
DK3079688T3 (da) 2018-01-29
MX372922B (es) 2020-04-27
EP3079688A1 (en) 2016-10-19
JP2016540000A (ja) 2016-12-22
HRP20180323T8 (hr) 2019-01-25
KR102280530B1 (ko) 2021-07-21
JP6419826B2 (ja) 2018-11-07
HUE036035T2 (hu) 2018-06-28
CA2932791C (en) 2021-11-09
CN105792824A (zh) 2016-07-20
NZ720868A (en) 2022-04-29
TN2016000213A1 (en) 2017-10-06
NO3079688T3 (https=) 2018-04-21
AU2014363428A1 (en) 2016-06-23
US20160303117A1 (en) 2016-10-20
KR20160088886A (ko) 2016-07-26
CA2932791A1 (en) 2015-06-18
PL3079688T3 (pl) 2018-05-30
HK1223563A1 (zh) 2017-08-04
AU2014363428B2 (en) 2019-09-12
UA117271C2 (uk) 2018-07-10
BR112016012552A8 (pt) 2022-11-08
LT3079688T (lt) 2018-02-12
MA39076A1 (fr) 2017-05-31
MX2016007612A (es) 2016-09-09
SA516371298B1 (ar) 2018-06-07
RS56931B1 (sr) 2018-05-31
SI3079688T1 (en) 2018-03-30
CN105792824B (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
CN104869993B (zh) 治疗阿尔茨海默病及相关疾病的组合疗法
PT3079688T (pt) Derivado de cromona como um antagonista do receptor d3 de dopamina para seu uso para o tratamento de transtorno do espectro autista
US12551474B2 (en) Use of pridopidine for the treatment of fragile X syndrome
US20250235443A1 (en) Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
US10251937B2 (en) Retro-inverso analogs of spadin display increased antidepressant effects
JP7277458B2 (ja) 神経学的疾患を治療するための方法および組成物
ES2935705T3 (es) Un ligando del receptor GABA A
ES2980780T3 (es) Derivados del carbamoil ciclohexano para el tratamiento del trastorno del espectro autista
OA17906A (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder.
HK1223563B (zh) 色酮衍生物作为多巴胺d3受体拮抗剂用於治疗自闭症谱系障碍的用途
RU2812786C2 (ru) Применение ролуперидона для лечения негативных симптомов и заболеваний, повышения нейропластичности и содействия нейрозащите
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
CN121604971A (zh) 用于治疗与焦虑症相关的认知障碍的hip/pap蛋白或其衍生物
Alfei Palloni et al. Learning experience determines the fate of fear memories after post-training manipulations
Jensen Serotonin: from mouse models to human disorders